http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014521696-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2012-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2014-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2014521696-A
titleOfInvention Quinazoline compounds as serine / threonine kinase inhibitors
abstract Compounds having formula (I), as defined herein, R 1 , R 2 , R 3 and Ar are inhibitors of ERK kinase. Compositions and methods for treating hyperproliferative disorders are also disclosed. The present invention relates to compounds useful for treating hyperproliferative and neoplastic diseases by inhibiting serine / threonine kinases and inhibiting signal transduction pathways that are generally over-active or over-expressed in cancer tissues. The compounds of the present invention are selective inhibitors of ERK (extracellular signal-regulated kinase). The invention further relates to a method of treating cancer or hyperproliferative diseases with compounds within the scope of the invention.
priorityDate 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009246198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009535393-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007520543-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419898619
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466494924
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11829372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465370077
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68294639

Total number of triples: 35.